Craniotomy with Major Device Implant DRG

DRG 023 addresses complex neurosurgical admissions involving major device implants or acute complex central nervous system diagnoses with Major Complication or Comorbidity, including antineoplastic implants and neurostimulator procedures; it captures high-resource inpatient care. This grouping matters for inpatient reimbursement because it aligns payment with the elevated procedural complexity, device-related costs, and intensive postoperative resources recognized by the Centers for Medicare & Medicaid Services.

DRG 023 Overview

DRG 023 covers hospitalizations for craniotomy with major device implant or acute complex central nervous system principal diagnosis with Major Complication or Comorbidity, as well as admissions for antineoplastic implant procedures or epilepsy treated with a neurostimulator. This Diagnosis-Related Group encompasses high-acuity neurosurgical interventions and device implantations that drive substantial resource use, extended operating room time, and specialized postoperative care. It matters for Medicare payment because cases grouped here typically receive higher inpatient reimbursement reflecting increased procedure complexity, device costs, and intensive care needs. Accurate clinical documentation of the procedures, device use, and comorbidities is key to appropriate grouping and payment under Centers for Medicare & Medicaid Services rules.

Acute perioperative device-implant safety and efficacy studies: randomized or observational studies assessing short-term outcomes and complication rates associated with major intracranial device implantation (such as ventricular shunts, deep brain stimulators, tumor-seeding catheters, or neurostimulation leads placed at the time of craniotomy) in patients undergoing craniotomy for complex CNS pathology or epilepsy. These trials focus on intraoperative and immediate postoperative morbidity, infection, device-related neurological deficits, and device functionality in the high-risk period, studying patients with acute complex CNS diagnoses or refractory epilepsy requiring device therapy. Results inform surgeons and hospital administrators about expected complication profiles, length of stay drivers, and resource needs that directly affect inpatient coding, utilization review, and payer authorization for device-related care.
Comparative effectiveness and timing-of-intervention studies for acute complex CNS diagnoses: prospective cohort or randomized studies comparing strategies such as early aggressive surgical resection with device implantation versus staged procedures or conservative medical management in patients with malignant or life‑threatening CNS pathology (for example hemorrhagic or neoplastic processes presenting with mass effect or rapidly evolving deficits). These studies examine functional neurologic outcomes, need for reoperation, ICU utilization, and in-hospital mortality among adults with MCC-level acuity, addressing which approaches yield the best balance of short-term survival and complication burden. Evidence from these trials is relevant to payers and hospitals for DRG-related resource allocation, triage protocols, and to justify decisions about intensive perioperative care and reimbursement for high-cost acute interventions.
Post-discharge functional outcomes, readmission, and cost-effectiveness studies: longitudinal observational or registry-based research tracking patients after craniotomy with major device or antineoplastic implant to measure long-term seizure control, neurological function, device longevity, readmission rates, and total episode-of-care costs including rehabilitation and complications. These studies enroll survivors of high-acuity craniotomy with MCCs and evaluate predictors of readmission, durable benefit from implants, and downstream utilization such as home health, skilled nursing, and repeat operations. Findings help case managers, payers, and value-based care programs understand the longer-term economic impact of index admissions in this DRG and guide policy on bundled payments, follow-up care pathways, and approval of costly implants or adjunct therapies.

Acute perioperative device-implant safety and efficacy studies: randomized or observational studies assessing short-term outcomes and complication rates associated with major intracranial device implantation (such as ventricular shunts, deep brain stimulators, tumor-seeding catheters, or neurostimulation leads placed at the time of craniotomy) in patients undergoing craniotomy for complex CNS pathology or epilepsy. These trials focus on intraoperative and immediate postoperative morbidity, infection, device-related neurological deficits, and device functionality in the high-risk period, studying patients with acute complex CNS diagnoses or refractory epilepsy requiring device therapy. Results inform surgeons and hospital administrators about expected complication profiles, length of stay drivers, and resource needs that directly affect inpatient coding, utilization review, and payer authorization for device-related care.
Comparative effectiveness and timing-of-intervention studies for acute complex CNS diagnoses: prospective cohort or randomized studies comparing strategies such as early aggressive surgical resection with device implantation versus staged procedures or conservative medical management in patients with malignant or life‑threatening CNS pathology (for example hemorrhagic or neoplastic processes presenting with mass effect or rapidly evolving deficits). These studies examine functional neurologic outcomes, need for reoperation, ICU utilization, and in-hospital mortality among adults with MCC-level acuity, addressing which approaches yield the best balance of short-term survival and complication burden. Evidence from these trials is relevant to payers and hospitals for DRG-related resource allocation, triage protocols, and to justify decisions about intensive perioperative care and reimbursement for high-cost acute interventions.
Post-discharge functional outcomes, readmission, and cost-effectiveness studies: longitudinal observational or registry-based research tracking patients after craniotomy with major device or antineoplastic implant to measure long-term seizure control, neurological function, device longevity, readmission rates, and total episode-of-care costs including rehabilitation and complications. These studies enroll survivors of high-acuity craniotomy with MCCs and evaluate predictors of readmission, durable benefit from implants, and downstream utilization such as home health, skilled nursing, and repeat operations. Findings help case managers, payers, and value-based care programs understand the longer-term economic impact of index admissions in this DRG and guide policy on bundled payments, follow-up care pathways, and approval of costly implants or adjunct therapies.

OpenPayer

Summary & Overview

Craniotomy with Major Device Implant or Complex CNS DRG 023: Inpatient Reimbursement Overview

DRG 023 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes